BONESUPPORT starts its own sales organization in the Netherlands

Report this content

Lund, Sweden, 15.00 CET, 8 June 2020 – BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces that the company is from 1 July 2020 starting direct sales within the Netherlands.

“We have a proven and scalable business model that has proved itself in a number of selected markets. We are now looking forward to adding the important Dutch market to our selected direct markets”, said Emil Billbäck, CEO of BONESUPPORT.

BONESUPPORT now has its own sales in Denmark, the Netherlands, Switzerland, the UK, Sweden and Germany. In other European markets and in other parts of the world, the company cooperates with specialist distributors. To date, BONESUPPORT has had a distributor in the Netherlands, which is allowed to sell in parallel with BONESUPPORT in the Netherlands until 31 December 2020.

For more information contact:



Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO
+46 (0) 46 286 53 70

Cord Communications
Charlotte Stjerngren
+46 (0) 708 76 87 87


BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The Company is conducting several clinical studies to further demonstrate the clinical and health economic benefits that its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2021. The Company is based in Lund, Sweden, and the net sales amounted to SEK 155 million in 2019. Please visit for more information.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

Documents & Links